Clinical Trial Update: TAK-228 and TAK-117 Followed by Cisplatin and Nab Paclitaxel for Metastatic Triple Negative Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial in metastatic triple negative breast cancer evaluating TAK-228 and TAK-117 followed by cisplatin and nab-paclitaxel has completed with posted resu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• CISPLATIN (cisplatin)
• Nab-paclitaxel (paclitaxel protein-bound)
• TAK-117
• TAK-228

Snippet

Sponsor: Joyce O'Shaughnessy | Conditions: Triple Negative Breast Cancer | Phase 2 | Status: COMPLETED | Results posted: 2023-05-09